Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
1.1 Abemaciclib (Verzenios)
1.2 Alpelisib (Piqray)
1.3 Fulvestrant (fulvestrant or Faslodex)
1.4 Palbociclib (Ibrance)
1.5 Ribociclib (Kisqali)
Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
Q3. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
Q4. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
4.1 Curative
4.2 Palliative
4.3 Not known / stated
Q5. How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
5.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)
5.2 Abemaciclib (Verzenios) + an aromatase inhibitor (anastrozole, letrozole or exemestane)
5.3 Abemaciclib (Verzenois) + tamoxifen
5.4 Abemaciclib monotherapy
5.5 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)
5.6 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)
5.7 Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)
5.8 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)
5.9 Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)
